ARCHITECT HBSAG QUALITATIVE, QUALITATIVE CONFIRMATORY, CONFIRMATORY MANUAL DILUENT, CALIBRATORS, AND CONTROLS

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P110029

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the architect hbsag qualitative, architect hbsag qualitative confirmatory, architect hbsag qualitative confirmatory manual diluent, architect hbsag qualitative calibrators, and architect hbsag qualitative controls. This device is indicated for: architect hbsag qualitative - the architect hbsag qualitative assay is a chemiluminescent microparticle immunoassay (cmia) for the qualitative detection of hepatitis b surface antigen (hbsag) in human adult and pediatric serum and plasma and neonate serum. The assay may also be used to screen for hbv infection in pregnant women to identify neonates who are at risk for acquiring hepatitis bduring the perinatal period. Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with the hepatitis b virus (hbv) (state of infection or associated disease not determined) in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis b infection. Not intended for use in screening blood, plasma, or tissue donors. Architect hbsag qualitative confirmatory - the architect hbsag qualitative confirmatory assay is a chemiluminescent microparticle immunoassay (cmia) for the qualitative confirmation of the presence of hepatitis b surface antigen (hbsag) in human adult and pediatric serum and plasma and neonate serum by means of specific antibody neutralization. Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with the hepatitis b virus (hbv) (state of infection or associated disease not determined) in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis b infection. Not intended for use in screening blood, plasma, or tissue donors. (for additional information, please refer to approval order).

DeviceARCHITECT HBSAG QUALITATIVE, QUALITATIVE CONFIRMATORY, CONFIRMATORY MANUAL DILUENT, CALIBRATORS, AND CONTROLS
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantAbbott Laboratories
Date Received2011-07-26
Decision Date2012-04-12
Notice Date2012-04-17
PMAP110029
SupplementS
Product CodeLOM
Docket Number12M-0372
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address Abbott Laboratories 100 Abbott Park Rd. dept 09v6, Bldg. Ap5-2 abbott Park, IL 60064-6088
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P110029Original Filing
S041 2023-01-06 30-day Notice
S040 2022-11-07 30-day Notice
S039 2022-09-14 30-day Notice
S038 2022-09-09 30-day Notice
S037 2022-07-18 30-day Notice
S036 2021-11-18 30-day Notice
S035 2021-11-09 30-day Notice
S034 2021-02-09 Real-time Process
S033 2020-07-02 30-day Notice
S032 2020-03-16 Normal 180 Day Track No User Fee
S031 2020-03-16 Normal 180 Day Track No User Fee
S030
S029 2019-08-01 Normal 180 Day Track
S028 2018-10-16 30-day Notice
S027 2018-06-27 30-day Notice
S026 2017-06-30 Real-time Process
S025
S024 2016-10-14 30-day Notice
S023 2016-03-10 30-day Notice
S022 2015-07-16 30-day Notice
S021 2015-06-15 30-day Notice
S020 2014-12-04 30-day Notice
S019 2014-11-14 30-day Notice
S018 2014-11-13 30-day Notice
S017 2014-03-18 30-day Notice
S016 2013-11-01 30-day Notice
S015 2013-10-30 30-day Notice
S014 2013-10-28 30-day Notice
S013 2013-09-24 30-day Notice
S012 2013-07-17 30-day Notice
S011 2013-02-11 30-day Notice
S010 2012-11-19 30-day Notice
S009 2012-11-15 30-day Notice
S008 2012-11-13 30-day Notice
S007 2012-11-01 30-day Notice
S006 2012-10-26 30-day Notice
S005 2012-09-17 30-day Notice
S004 2012-08-17 30-day Notice
S003 2012-08-03 30-day Notice
S002 2012-06-06 30-day Notice
S001 2012-05-01 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.